Brainstorm Cell Therapeutics Inc. Stock News

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI ) Q4 2024 Earnings Conference Call March 31, 2025 8:30 AM ET Company Participants Michael Wood - Investor Relations Chaim Lebovits - President & Chief Executive Officer Alla Patlis - Interim Chief Financial Officer Bob Dagher - Executive Vice President & Chief Medical Officer Haro Hartounian - Executive Vice President & Chief Operating Officer Conf...

Conference call and webcast at 8:30 a.m. Eastern Time today NEW YORK , March 31, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the fiscal year ended December 31, 2024, and provided a corporate update.

NEW YORK , March 26, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading biotechnology company committed to the development and commercialization of best-in-class autologous cellular therapies for the treatment of neurodegenerative diseases, today announced that it has been granted the exact compliance extension it requested from the Nasdaq Hearings Panel through Ju...

Call Scheduled for March 31, 2025, at 8:30 AM Eastern Time NEW YORK , March 24, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it will hold a conference call and webcast to update shareholders on financial results for the fourth quarter and year ended December 31, 202...

NEW YORK , Dec. 30, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today issued a Letter to shareholders.     Dear Valued Shareholders, 2024 has been a very productive year for BrainStorm Cell Therapeutics, defined by remarkable milestones and achievements that have brought us closer to o...

Call Scheduled for December 30, 2024, at 8:30 AM ET; Additionally, Key Opinion Leader Webinar on ALS Advancements to Take Place on December 11, 2024 NEW YORK , Dec. 9, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it will hold a conference call and webcast on Decembe...

NEW YORK , Dec. 3, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it has received Notice of Allowance from the U.S. Patent & Trademark Office (USPTO) for patent application 16/981,757 which covers its proprietary exosome technology.    The patent describes the composi...

NEW YORK , Dec. 2, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will host a key opinion leader (KOL) webinar on Wednesday, December 11, 2024 at 10:00 AM ET. To register, click here.